JAMA Psychiatry: Clinical trials have confirmed that this "psychedelic mushroom" can actually treat depression with significant effects

When it comes to mushrooms, I believe most people will immediately think of delicious food

The psychedelic mushroom is just such a hallucinogenic mushroom.

On November 9, 2021, Compass Pathways issued a statement, announcing the results of the largest ever clinical trial of psilocybin in the treatment of major depression.

Major Depressive Disorder (MDD) affects more than 300 million people worldwide and is a major public health problem

More importantly, the current drugs used to treat depression are very limited and often have serious side effects

Psilocybin (psilocybin) shows joint activity with common depression treatment drugs (serotonergic and glutaminergic drugs)

Prior to this, on November 4, 2020, researchers from Johns Hopkins University School of Medicine in the United States published in the JAMA sub-Journal JAMA Psychiatry entitled: Effects of Psilocybin-Assisted Therapy on Major Depressive Disorder A Randomized Clinical Trial Test thesis

This new clinical study shows that psilocybin, the effective chemical component of psychedelic mushrooms, can effectively improve the symptoms of patients with major depression (MDD), and has the advantages of rapid response, long-lasting efficacy and small side effects.

In this regard, Dr.

The results of the largest clinical trial of psilocybin in the treatment of depression announced by Compass Pathways this time further confirmed the great potential of psilocybin for the treatment of depression

The results of this clinical trial have not yet been published, and the specific details are not yet known.

Original source:

Alan K.